Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.58 |
| ▸ | KIF11 | P52732 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.50 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17808228 | 0.86 | MAP4K4 (0.54) | PTGS2KIF11PTGS1MAP4K4PIK3CA | |
| SCHEMBL24363062 | 0.85 | PTGS2 (0.67) | PTGS2KIF11PTGS1ABCC4ABCB11 | |
| SCHEMBL17813809 | 0.80 | POLB (0.47) | PTGS2IDO1 | |
| SCHEMBL16454400 | 0.78 | KDM4E (0.46) | — | |
| SCHEMBL22795814 | 0.78 | PDE3B (0.51) | PTGS2PIK3CAIDO1 | |
| SCHEMBL16455583 | 0.78 | MAPT (0.46) | NR1H2 | |
| SCHEMBL16454402 | 0.75 | CYP11B2 (0.50) | KIF11PIK3CA | |
| SCHEMBL17394027 | 0.75 | GLA (0.56) | PTGS2KIF11MAP4K4PIK3CAKCNH2 | |
| SCHEMBL6721511 | 0.73 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL22796288 | 0.73 | AKR1C3 (0.52) | PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611248-B2 | Chemical compounds | SYNGENTA LIMITED (GB) | 2017-04-04 | — | — | US | disclosed |
| US-20160159767-A1 | CHEMICAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-09 | — | — | US | disclosed |
| WO-2015018432-A1 | PYRROLONE DERIVATIVES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159767-A1 | CHEMICAL COMPOUNDS | DDT, CBR3, CYP1B1 | PTGS2 1278/4885KIF11 3376/4885PTGS1 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.